Cargando…
p27(Kip1) V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor–positive breast cancer
CDK4/6 inhibitors benefit a minority of patients who receive them in the breast cancer adjuvant setting. p27(Kip1) is a protein that inhibits CDK/Cyclin complexes. We hypothesized that single-nucleotide polymorphisms that impaired p27(Kip1) function could render patients refractory to endocrine ther...
Autores principales: | Mouron, Silvana, Bueno, Maria J, Muñoz, Manuel, Torres, Raul, Rodríguez, Sandra, Apala, Juan V, Silva, Jorge, Sánchez-Bayona, Rodrigo, Manso, Luis, Guerra, Juan, Rodriguez-Lajusticia, Laura, Malon, Diego, Malumbres, Marcos, Quintela-Fandino, Miguel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035773/ https://www.ncbi.nlm.nih.gov/pubmed/36806942 http://dx.doi.org/10.1093/jncics/pkad014 |
Ejemplares similares
-
Nintedanib plus letrozole in early breast cancer: a phase 0/I pharmacodynamic, pharmacokinetic, and safety clinical trial of combined FGFR1 and aromatase inhibition
por: Quintela-Fandino, Miguel, et al.
Publicado: (2019) -
FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1
por: Mouron, Silvana, et al.
Publicado: (2021) -
Monitoring vascular normalization: new opportunities for mitochondrial inhibitors in breast cancer
por: Mouron, Silvana, et al.
Publicado: (2021) -
Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach
por: Bueno, Maria J, et al.
Publicado: (2017) -
Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A
por: Mouron, S., et al.
Publicado: (2022)